Chiesi in-licenses DPP1 inhibitor from Haisco Pharma

Italian family-owned drugmaker Chiesi Farmaceutici has added another investigational product to its list of in-licensed investigational meds, as well as the $1.25 billion acquisition of Anglo-Irish firm Amryt Pharma, this year alone.

This time, Chiesi said it has executed a license agreement with China-based Haisco Pharmaceutical to develop, manufacture, and commercialize outside China and adjacent territories (Hong Kong SAR, Macau SAR and Taiwan District) HSK31858, a novel, reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.

Chiesi explained that HSK31858 is an oral, potent, and highly selective small molecule DPP1 inhibitor currently in Phase II trials in China with the potential to be an anti-inflammatory agent in bronchiectasis.